Dust Mite-Related Asthma

Sublingual immunotherapy for house dust mite allergic asthma improved bronchial epithelial antiviral resistance to viral infection, according to a study published in the American Journal of Respiratory and Critical Care Medicine.

Subcutaneous immunotherapy for house dust mite allergy may slightly protect patients against SARS-CoV-2 infection, especially after the dose-escalation phase, according to a letter published in Clinical and Translational Allergy.

House dust mite sublingual immunotherapy tablets reduced inhaled corticosteroid use among patients with mild to moderate allergic asthma, according to a systematic review in The Journal of Allergy and Clinical Immunology: In Practice.